Recordati Stock Quote REC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

52.10

Bid

50.30

Ask

52.30

Volume

249,235

50.75 Day's Range 52.10

43.88 52 Week Range 54.80

Market Cap

10.699B

Previous Close

50.65

Open

50.85

Last Trade

330

52.1

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

249,564

Shares Outstanding

205,358,104

Dividend Yield

2.36%

PE Ratio

27.57

Earnings Per Share (EPS)

1.9

Revenue

2.07B

Net Profit

389.21M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.recordati.it

Headquarters

Milan, Lombardy, Ita

Founded

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 50.65 €. Over the last year, Recordati shares have traded in a share price range of 43.88 € to 54.80 €.

Recordati currently has 205,358,104 shares outstanding. The market capitalization of Recordati is 10.40 € billion. Recordati has a price to earnings ratio (PE ratio) of 27.57.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.55	1.06692531523	51.55	52.1	49.48	269772	50.26812464	DE
4	-1.6	-2.97951582868	53.7	54.45	48.58	271044	51.60431466	DE
12	-0.5	-0.950570342205	52.6	54.8	48.58	249564	51.8131682	DE
26	3.56	7.33415739596	48.54	54.8	47.28	240391	50.69836484	DE
52	7.06	15.674955595	45.04	54.8	43.88	233788	50.26789161	DE
156	-4.12	-7.32835289932	56.22	56.96	34.52	236144	45.8259254	DE
260	14.35	38.0132450331	37.75	57.9	28.26	283056	44.69751111	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WTFINTrevi Finanziaria Industriale Spa	1.30 € (28.71%)	31
PLCPlc Spa	1.775 € (18.73%)	167.84k
1SMCISuper Micro Computer Inc	31.53 € (16.35%)	28.42k
1MRNAModerna Inc	40.565 € (15.24%)	6.47k
COSMOFarmacosmo spa	0.43 € (12.86%)	93.07k
WISC24Integrated System Credit Consulting Fintech Spa	0.0035 € (-49.28%)	50k
ECNLAAAquafil SpA	0.039 € (-18.07%)	314.46k
1SYMSymrise AG	105.00 € (-17.13%)	62
WIVN26iVision Tech SpA	0.25 € (-16.67%)	6.51k
1EVTEvotec SE	8.26 € (-16.57%)	7.02k
TITTelecom Italia SpA	0.2317 € (0.78%)	106.93M
ISPIntesa Sanpaolo Spa	3.631 € (-1.00%)	95.09M
SPMSaipem Spa	2.399 € (1.18%)	56.12M
ENELEnel Spa	6.73 € (2.28%)	29.44M
RNRisanamento	0.0245 € (4.70%)	20.21M